
Quarterly report 2022-Q2
added 08-09-2022
Epizyme Market Cap 2011-2026 | EPZM
As of March 24, 2026 Epizyme has a market cap of $ 249 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 103 M | 1.11 B | 1.92 B | 732 M | 1.06 B | 557 M | 362 M | 632 M | 520 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.92 B | 103 M | 776 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.33 | 0.91 % | $ 8.01 B | ||
|
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
1.86 B | $ 14.11 | -3.13 % | $ 1.9 B | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | ||
|
BioVie
BIVI
|
2.44 M | $ 1.29 | -3.31 % | $ 1.91 M | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
7.37 B | $ 216.01 | -0.94 % | $ 5 B | ||
|
BioNTech SE
BNTX
|
62.9 B | $ 86.86 | -1.75 % | $ 27.2 B | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 19.42 | 0.99 % | $ 908 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
127 M | $ 8.18 | -3.02 % | $ 109 M | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
CytomX Therapeutics
CTMX
|
931 M | $ 4.2 | -5.83 % | $ 579 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
28.2 M | $ 0.73 | 20.26 % | $ 8.36 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | ||
|
Eton Pharmaceuticals
ETON
|
559 M | $ 22.9 | -3.82 % | $ 616 M | ||
|
Exelixis
EXEL
|
11.7 B | $ 41.46 | 0.12 % | $ 11.3 B | ||
|
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.35 | -3.34 % | $ 344 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
1.82 M | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
15.8 M | $ 2.6 | -1.14 % | $ 16.3 M | ||
|
Fulcrum Therapeutics
FULC
|
539 K | $ 6.64 | -3.63 % | $ 421 K | ||
|
Atreca
BCEL
|
49 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | ||
|
Genmab A/S
GMAB
|
25 B | $ 25.62 | -0.23 % | $ 16.4 B | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
Grifols, S.A.
GRFS
|
8.42 B | $ 7.6 | -1.24 % | $ 6.83 B | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B | ||
|
Halozyme Therapeutics
HALO
|
9.66 B | $ 61.92 | -1.5 % | $ 7.42 B | ||
|
Bellerophon Therapeutics
BLPH
|
78.6 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Immatics N.V.
IMTX
|
503 M | $ 9.4 | -1.16 % | $ 591 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
847 M | $ 4.29 | -2.94 % | $ 822 M | ||
|
Incyte Corporation
INCY
|
19.5 B | $ 90.93 | 0.53 % | $ 17.7 B | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M |